SHSE:600062's Days Payable is ranked worse than 72.23% of 922
companies
in the Drug Manufacturers industry
Industry Median: 90.61
vs SHSE:600062: 54.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Days Payable Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
China Resources Double-Crane Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Days Payable of 49.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is 19% below median its historical median of 60.80. Over the past decade, China Resources Double-Crane Pharmaceutical Co's Days Payable has ranged from 54.52 to 89.29. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #666 out of 922 companies in the Drug Manufacturers industry, placing it in the top 72.2%.
Is China Resources Double-Crane Pharmaceutical Co's Days Payable too high?
China Resources Double-Crane Pharmaceutical Co's current Days Payable of 49.00 is 19% below median its 10-year median of 60.80. Over the past 10 years, this metric has ranged from a low of 54.52 to a high of 89.29. The Drug Manufacturers industry median Days Payable is 90.61. China Resources Double-Crane Pharmaceutical Co's value of 49.00 is 45.9% below this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #666 out of 922 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #666 out of 922 companies for Days Payable. This places China Resources Double-Crane Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.61. China Resources Double-Crane Pharmaceutical Co's value of 49.00 is 45.9% below this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own Days Payable has ranged from 54.52 to 89.29 over the past decade. While the company's 10-year median is 60.80 vs. the industry median of 90.61, China Resources Double-Crane Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.61, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current Days Payable of 49.00 is 45.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current Days Payable is 49.00, which is 19% below median its own 10-year median of 60.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.75, compared to a current price of ¥16.43 — trading 12.4% below its estimated fair value. The current Days Payable is 49.00, which is 19% below median its 10-year median of 60.80 and 45.9% below the Drug Manufacturers industry median of 90.61. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Days Payable is 49.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.43 is trading 12.4% below its estimated GF Value™ of ¥18.75.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
Days Payable: 49.00 (19% below median its 10-year median of 60.80)
GF Value™: ¥18.75 vs. price of ¥16.43 (12.4% below fair value)
Industry Position: 45.9% below the Drug Manufacturers median (#666 of 922)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
